A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5210-5217

  De Graan, Anne Joy M ^a   Elens, Laure ^a   Smid, Marcel ^a   Martens, John W ^a   Sparreboom, Alex ^a,b   Nieuweboer, Annemieke J M ^a   Friberg, Lena E ^b   Elbouazzaoui, Samira ^a   Wiemer, Erik A C ^a   Van Der Holt, Bronno ^a   Verweij, Jaap ^a   Van Schaik, Ron H N ^a   Mathijssen, Ron H J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSPORT; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; GENETIC MODEL; GENETIC VARIABILITY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PHARMACOGENETICS; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84884557299     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0487     Document Type: Article

References (39)

1. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
2. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005;4:815-8.
3. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 2005;116:824-9.
4. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 2006;12:6125-32.
5. Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 2007;25:4528-35.
6. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, et al. Association of ABCB1 genotypes with paclitaxelmediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42:2893-6.
7. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function, and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007;7:154-79.
8. Bergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8 3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J 2011;11:113-20.
9. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104:130-7.
10. Leskela S, Jara C, Leandro-Garcia LJ, Martinez A, Garcia-Donas J, Hernando S, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 2011;11:121-9.
11. Product information Taxol: http://packageinserts.bms.com/pi/pi-taxol.pdf) . Accessed [August 1st, 2013].
12. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine (2007). http://medicine. iupui.edu/clinpharm/ddis/table.aspx. Accessed [August 1st, 2013].
13. Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998;705:159-64.
14. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Cancer Biol Ther 2006;5:833-9.
15. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom A. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001;19:4065-73.
16. Henningsson A. Population Pharmacokinetic Model for Cremophor EL. Annual meeting of the Population Approach Group in Europe: Population Approach Group in Europe; 2005.
17. Henningsson A, Sparreboom A, Sandstrom M, Freijs A, Larsson R, Bergh J, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003;39:1105-14.
18. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. Cancer Chemother Pharmacol 2001;47:309-18.
19. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
20. Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, et al. Comprehensive assessment of metabolic enzyme and transporter genes using the affymetrix targeted genotyping system. Pharmacogenomics 2007;8:293-305.
21. Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clin Cancer Res 2006;12:2150-7.
22. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med 2011;2:879-85.
23. Kummel S, Thomas A, Jeschke S, Hauschild M, Sehouli J, Lichtenegger W, et al. Postoperative therapy modalities for cervical carcinoma. Anticancer Res 2006;26:1707-13.
24. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21.
25. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
26. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet 2013;14:23-34.
27. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
28. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.
29. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93.
30. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005;45:674-82.
31. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12:854-9.
32. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, et al. CYP2C8 3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 2012;134:401-10.
33. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005;11:8097-104.
34. *22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 2013;19:3316-24.
35. Edvardsen H, Irene Grenaker Alnaes G, Tsalenko A, Mulcahy T, Yuryev A, Lindersson M, et al. Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds. Pharmacogenet Genomics 2006;16:207-17.
36. Edvardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, et al. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. Pharmacogenomics J 2010;10:513-23.
37. Ikeda R, Vermeulen LC, Lau E, Jiang Z, Sachidanandam K, Yamada K, et al. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells. Int J Oncol 2011;38:513-9.
38. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007;12:913-23.
39. Peters EJ, Motsinger-Reif A, Havener TM, Everitt L, Hardison NE, Watson VG, et al. Pharmacogenomic characterization of US FDAapproved cytotoxic drugs. Pharmacogenomics 2011;12:1407-15.